trastuzumab

Known as: Anti-p185-HER2, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-c-ERB-2 
A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies… (More)
National Institutes of Health

Related topics

Related topics

19 relations

Narrower (3)

ABP 980HerceptinPF-05280014
AC-T-T RegimenAntibody-Dependent Cellular CytotoxicityDrug AllergyERBB2 protein, human
(More)

Broader (1)

Antineoplastic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Strategies and challenges for the next generation of antibody–drug conjugates
Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research… (More)
  • figure 2
  • figure 3
  • table 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
BACKGROUND The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised…
BACKGROUND Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
PURPOSE Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
BACKGROUND Trastuzumab--a humanised monoclonal antibody against HER2--has been shown to improve disease-free survival after… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2007
Review
2007
Trastuzumab--mechanism of action and use in clinical practice.
Rather than too few patients and events[1], low efficacy is the likelier cause of lacking significant improvements in disease… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
A BSTRACT Background The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25… (More)
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
BACKGROUND Trastuzumab (Herceptin), an anti-HER2/neu receptor monoclonal antibody that inhibits growth of ErbB2-overexpressing… (More)
  • figure 1
  • figure 2
Is this relevant?